What's a Priority Review Voucher worth?
That's a complicated question now that the first voucher used on an application – from drug maker Novartis AG...
Ilaris Complete Response Letter Raises Questions About The Validity of Priority Review Vouchers
What’s a Priority Review Voucher worth? That’s a complicated question now that the first voucher used on an application, from drug maker Novartis AG for Ilaris (canakinumab), has received a complete response letter from US regulators.
More from Archive
More from In Vivo
• By
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
• By
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.